These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 28027446)

  • 1. Current Trends in Multidrug Optimization: An Alley of Future Successful Treatment of Complex Disorders.
    Weiss A; Nowak-Sliwinska P
    SLAS Technol; 2017 Jun; 22(3):254-275. PubMed ID: 28027446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Trends in Multidrug Optimization.
    Weiss A; Nowak-Sliwinska P
    J Lab Autom; 2016 Dec; ():2211068216682338. PubMed ID: 28095178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index.
    Kashif M; Andersson C; Hassan S; Karlsson H; Senkowski W; Fryknäs M; Nygren P; Larsson R; Gustafsson MG
    Sci Rep; 2015 Sep; 5():14118. PubMed ID: 26392291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug discovery strategies in the field of tumor energy metabolism: Limitations by metabolic flexibility and metabolic resistance to chemotherapy.
    Amoedo ND; Obre E; Rossignol R
    Biochim Biophys Acta Bioenerg; 2017 Aug; 1858(8):674-685. PubMed ID: 28213330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model.
    Silva A; Lee BY; Clemens DL; Kee T; Ding X; Ho CM; Horwitz MA
    Proc Natl Acad Sci U S A; 2016 Apr; 113(15):E2172-9. PubMed ID: 27035987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple target drug cocktail design for attacking the core network markers of four cancers using ligand-based and structure-based virtual screening methods.
    Wong YH; Lin CL; Chen TS; Chen CA; Jiang PS; Lai YH; Chu L; Li CW; Chen JJ; Chen BS
    BMC Med Genomics; 2015; 8 Suppl 4(Suppl 4):S4. PubMed ID: 26680552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors.
    Ocaña A; Freedman O; Amir E; Seruga B; Pandiella A
    Cancer Metastasis Rev; 2014 Mar; 33(1):295-307. PubMed ID: 24338003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3D Culture as a Clinically Relevant Model for Personalized Medicine.
    Fong ELS; Toh TB; Yu H; Chow EK
    SLAS Technol; 2017 Jun; 22(3):245-253. PubMed ID: 28277923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling.
    Sandercock AM; Rust S; Guillard S; Sachsenmeier KF; Holoweckyj N; Hay C; Flynn M; Huang Q; Yan K; Herpers B; Price LS; Soden J; Freeth J; Jermutus L; Hollingsworth R; Minter R
    Mol Cancer; 2015 Jul; 14():147. PubMed ID: 26227951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unlocking the Potential of High-Throughput Drug Combination Assays Using Acoustic Dispensing.
    Chan GK; Wilson S; Schmidt S; Moffat JG
    J Lab Autom; 2016 Feb; 21(1):125-32. PubMed ID: 26160862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human-cell-derived organoids as a new ex vivo model for drug assays in oncology.
    Mebarki M; Bennaceur A; Bonhomme-Faivre L
    Drug Discov Today; 2018 Apr; 23(4):857-863. PubMed ID: 29428171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic quantitative characterization of cellular responses induced by multiple signals.
    Al-Shyoukh I; Yu F; Feng J; Yan K; Dubinett S; Ho CM; Shamma JS; Sun R
    BMC Syst Biol; 2011 May; 5():88. PubMed ID: 21624115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer Drug Development Using Drosophila as an in vivo Tool: From Bedside to Bench and Back.
    Yadav AK; Srikrishna S; Gupta SC
    Trends Pharmacol Sci; 2016 Sep; 37(9):789-806. PubMed ID: 27298020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of drug combinations using Feedback System Control.
    Nowak-Sliwinska P; Weiss A; Ding X; Dyson PJ; van den Bergh H; Griffioen AW; Ho CM
    Nat Protoc; 2016 Feb; 11(2):302-15. PubMed ID: 26766116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical optimization of a broad-spectrum anti-bladder cancer tri-drug regimen via the Feedback System Control (FSC) platform.
    Liu Q; Zhang C; Ding X; Deng H; Zhang D; Cui W; Xu H; Wang Y; Xu W; Lv L; Zhang H; He Y; Wu Q; Szyf M; Ho CM; Zhu J
    Sci Rep; 2015 Jun; 5():11464. PubMed ID: 26088171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aiming for zero blindness].
    Nakazawa T
    Nippon Ganka Gakkai Zasshi; 2015 Mar; 119(3):168-93; discussion 194. PubMed ID: 25854109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. drexplorer: A tool to explore dose-response relationships and drug-drug interactions.
    Tong P; Coombes KR; Johnson FM; Byers LA; Diao L; Liu DD; Lee JJ; Heymach JV; Wang J
    Bioinformatics; 2015 May; 31(10):1692-4. PubMed ID: 25600946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Network-based approaches for drug response prediction and targeted therapy development in cancer.
    Dorel M; Barillot E; Zinovyev A; Kuperstein I
    Biochem Biophys Res Commun; 2015 Aug; 464(2):386-91. PubMed ID: 26086105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.